radiolabelled MMP inhibitors; iodine-123; in vitro assay; in vivo biodistribution; SPECT; tumor imaging
Abstract :
[en] Several studies have demonstrated a positive correlation between tumor progression and expression of extracellular proteinases such as matrix metalloproteinases (MMPs). MMP-2 and MMP-9 have become attractive targets for cancer research because of their increased expression in human malignant tumor tissues of various organs, providing a target for medical imaging techniques. Radioiodinated carboxylic and hydroxamic MMP inhibitors 2-(4'-[123]iodo-biphenyl-4-sulfonylainino)-3-(1H-indol-3-yl)-propionic acid (9) and 2-(4'-[I-123] iodo-biphenyl-4-sulfonylamino)-3-(1H-indol-3-yl)-propionamide (11) were synthesized by electrophilic aromatic substitution of the tributylstannyl derivatives and resulted in radiochemical yields of 60% +/- 5% (n - 3) and 70% +/- 5% (n = 6), respectively. In vitro zymography and enzyme assays showed high inhibition capacities of the inhibitors on gelatinases. In vivo biodistribution showed no long-terin accumulation in organs and the possibility to accumulate in the tumor. These results warrant further studies of radioiodinated carboxylic and hydroxamic MNIP inhibitor tracers as potential SPECT tumor imaging agents. (C) 2004 Elsevier Inc. All rights reserved.
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Oltenfreiter, Ruth; Ghent University
Staelens, Ludovicus; Ghent University
Lejeune, Annabelle ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases biologic activity and clinical implications. J Clin Oncol. 18:2000;1135-1149.
Noël A., Albert V., Bajou K., Bisson C., Devy L., Frankenne F., Maquoi E., Masson V., Sounni N.E., Foidart J.M. New functions of stromal proteases and their inhibitors in tumor progression. Surg Oncol Clin North Am. 10:2001;417-432.
Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev. 2:2002;161-174.
Coussens L.M., Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 3:1996;895-904.
Fei X., Zheng Q.H., Liu X., Wang J.Q., Sun H.B., Mock B.H., Stone K.L., Miller K.D., Sledge G.W., Hutchins G.D. Synthesis of radiolabelled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorg Med Chem Lett. 13:2003;2217-2222.
Vihinen P., Kähäri V.M. Matrix metalloproteinases in cancer prognostic markers and therapeutic targets. Int J Cancer. 99:2002;157-166.
O'Brien P.M., Ortwine D.F., Pavlovsky A.G., Picard J.A., Sliskovic D.R., Roth B.D., Dyer L.L., Johnson R.D., Man C.F., Hallak H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 43:2000;156-166.
Bremer C., Bredow S., Mahmood U., Weissleder R., Tung C.H. Optical imaging of matrix metalloproteinase-2 activity in tumors feasibility study in a mouse model. Radiology. 221:2001;523-529.
Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 189:1999;300-308.
Fang J, Shing, Wiederschain D. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 2000;97:3884-9.
Furumoto S., Iwata R., Ido T. Design and synthesis of fluorine-18 labelled matrix metalloproteinase inhibitors for cancer imaging. J Label Comp Radiopharmacol. 45:2002;975-986.
Brown P.D., Bloxidge R.E., Anderson E., Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metast. 11:1993;183-190.
Cai M., Onoda K., Takao M., Kyoko I.Y., Shimpo H., Yoshida T., Yada I. Degradation of Tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrece in early stage non-small cell lung cancer. Clin Cancer Res. 8:2002;1152-1156.
Davies B., Miles D.W., Happerfield L.C., Naylor M.S., Bobrow L.G., Rubens R.D., Balkwill F.R. Activity of type IV collagenases in benign and malignant breast desease. Br J Cancer. 67:1993;1126-1131.
Furumoto S., Takashima K., Kubota K., Ido T., Iwata R., Fukuda H. Tumor detection using F-18-labelled matrix metalloproteinase-2 inhibitor. Nucl Med Biol. 30:2003;119-125.
Kossakowska A.E., Huchcroft S.A., Urbanski S.J. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant, non-Hodgkin's lymphomas in humans. Br J Cancer. 73:1996;1401-1408.
Lee K.S., Rha S.Y., Kim S.J. Seuential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis. 14:1996;512-519.
Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., Balkwill K. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenaes in colorectal cancer. Cancer Res. 56:1996;190-196.
Passlick B., Sienel W., Seen-Hibler R., Wöckel W., Thetter O., Mutschler W., Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 6:2000;3944-3948.
Ylisirniö S., Höyhtyä M., Turpeeniemi-Hujanen T. Serum metalloproteinasese -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res. 20:2000;1311-1316.
Kuhnast B., Bodenstein C., Wester H.E., Weber W. Carbon-11-labelling of an N-Sulfanylamino acid derivative a potential tracer for MMP-2 and MMP-9 imaging. J Label Compd Radiopharm. 46:2003;539-553.
Zheng Q.H., Fei X., Liu X., Wang J.Q., Sun H.B., Mock B.M., Stone K.L., Martinez T.D., Miller K.D., Sledge G.W., Hutchins G.D. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl- halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol. 29:2002;761-770.
Hagmann W.K., Lark M.W., Becker J.W. Inhibition of matrix metalloproteinases. Bristol J.A. Annual reports in medical chemistry. 1996;231-240 Academic Press, New York.
Summers J.B., Davidsen S.K. Matrix metalloproteinase inhibitors and cancer. Bristol J.A. Annual reports in medical chemistry. 1998;131-140 Academic Press, New York.
Kiyama R., Tamura Y., Watanabe F., Tsuzuki H., Ohtani M., Yodo M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J Med Chem. 42:1999;1723-1738.
Tamura Y., Watanabe F., Nakatani T., Yasui K., Fuji M., Komurasaki T., Tsuzuki H., Maekawa R., Yoshioka T., Kawada K., Sugita K., Ohtani M. Higly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2) N-sulfonylamino acid derivatives. J Med Chem. 41:1998;640-649.
Hanessian S., Moitessier N., Gauchet C., Viau M. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases further probing of the S1, S1′, S2 ′ pockets. J Med Chem. 44:2001;3066-3073.
Maquoi E., Frankenne F., Baramova E., Munaut C., Sounni N.E., Remacle A., Noël A., Murphy G., Foidart J.M. Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem. 275:2000;11368- 11378.
Hawkes S.P., Li H., Taniguchi G.T. Zymography and reverse zymography for detecting MMPs and TIMPs. Clark I. Methods in Molecular Biology. 2001;399-410 Humana Press, Totowa, NJ.
Whittaker M., Flooyd C.D., Brown P., Gearing A.J.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 99:1999;2735-2776.
Massa S., Artico M., Corelli F., Mai A., Di Santo R., Cortes S., Marongiu M.E., Pani A., La Colla P. Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. J Med Chem. 33:1990;2845-2849.
Natchus M.G., Bookland R.G., De B., Almstead N.G., Pikul S., Janusz M.J., Heitmeyer S.A., Hookfin E.B., Hsieh L.C., Dowty M.E., Dietsch C.R., Patel V.S., Garver S.M., Gu F., Pokross M.E., Mieling G.E., Baker T.R., Foltz D.J., Peng S.X., Bornes D.M., Strojnowski M.J., Taiwo Y.O. Development of new hydroxamic matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J Med Chem. 43:2000;4948-4963.
Scozzafava A., Supuran C.T. Protease inhibitors Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. J Med Chem. 43:2000;1858-1865.